Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Clal Biotechnology Industries Ltd. focuses on investments in biotechnology companies, primarily in Israel and the U.S. Its portfolio includes companies developing innovative therapies and technologies in areas such as immunotherapy and regenerative medicine. The company's strategic partnerships and access to cutting-edge research provide a competitive edge in the rapidly evolving biotech sector.
Clal Biotechnology generates revenue primarily through equity stakes in biotechnology firms, benefiting from capital appreciation and potential exit strategies such as IPOs or acquisitions. The company leverages its expertise in identifying high-potential biotech ventures, providing it with a competitive advantage in a niche market.
Success of portfolio companies in clinical trials, particularly in immunotherapy and regenerative medicine
Strategic partnerships or collaborations with larger pharmaceutical firms
Market sentiment towards the biotechnology sector, influenced by FDA approvals
Changes in regulatory environments affecting biotech investments
Technological disruption in biotechnology could render current investments obsolete.
Regulatory changes could impact the approval process for new therapies.
Emergence of new biotech firms with innovative therapies could dilute market share.
Increased competition for funding from venture capital could limit available resources.
High operating losses leading to potential liquidity issues.
Dependence on the success of a few key portfolio companies.
moderate - The biotechnology sector can be sensitive to economic cycles, as funding for R&D may fluctuate with overall economic conditions.
Higher interest rates can increase the cost of capital for biotech firms, potentially slowing down investment in R&D and affecting valuations.
minimal - Clal Biotechnology's operations are not heavily reliant on credit markets.
growth - Investors looking for high-risk, high-reward opportunities in the biotech space.
high - The stock exhibits high volatility due to the speculative nature of biotech investments.
